Union Bancaire Privee UBP SA Reduces Stock Holdings in Johnson & Johnson $JNJ

Union Bancaire Privee UBP SA cut its holdings in Johnson & Johnson (NYSE:JNJ) by 2.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 157,258 shares of the company’s stock after selling 3,263 shares during the quarter. Union Bancaire Privee UBP SA’s holdings in Johnson & Johnson were worth $29,159,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after purchasing an additional 3,085,180 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Johnson & Johnson by 2.1% during the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock worth $9,227,988,000 after buying an additional 1,225,676 shares during the period. Norges Bank acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $4,877,174,000. Bank of New York Mellon Corp raised its stake in Johnson & Johnson by 2.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock worth $3,635,832,000 after acquiring an additional 620,039 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Johnson & Johnson by 0.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock worth $2,894,979,000 after acquiring an additional 52,074 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on JNJ. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Royal Bank Of Canada set a $240.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Finally, Raymond James Financial raised their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $208.85.

Johnson & Johnson Trading Up 0.6%

Johnson & Johnson stock opened at $210.50 on Thursday. The firm has a market cap of $507.14 billion, a PE ratio of 20.32, a P/E/G ratio of 2.27 and a beta of 0.36. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $215.18. The stock’s 50 day simple moving average is $197.44 and its two-hundred day simple moving average is $178.46. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.